| Market Cap | 1.36B 1.21B 1.13B 1.03B 1.94B 131B 1.95B 13.6B 5.29B 67.01B 5.11B 5.01B 215B | P/E 2026 * |
-4.94x | P/E 2027 * | -3.89x |
|---|---|---|---|---|---|
| Enterprise Value | 1.27B 1.13B 1.06B 960M 1.81B 123B 1.83B 12.72B 4.95B 62.68B 4.78B 4.68B 202B | EV / Sales 2026 * |
30.4x | EV / Sales 2027 * | 20.2x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 31/12/2006 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 14/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 30/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 31/07/2000 |
Robert Chess
CHM | Chairman | 69 | 30/04/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 31/01/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.36B | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.69B | |
| 0.00% | -1.42% | +22.95% | +78.76% | 58.81B | |
| -0.50% | -0.21% | +6.26% | +33.80% | 48.45B | |
| -0.43% | -3.38% | +325.88% | +678.68% | 42.84B | |
| -1.67% | -4.36% | +28.01% | +28.86% | 42.79B | |
| +0.19% | -1.18% | +5.86% | +109.29% | 41.25B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.13B | |
| -2.07% | +1.16% | +35.00% | +26.28% | 30.28B | |
| -0.27% | -3.28% | -10.35% | -13.02% | 24.05B | |
| Average | -0.17% | -0.25% | +52.46% | +121.05% | 43.81B | |
| Weighted average by Cap. | +0.30% | -0.54% | +55.38% | +127.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.88M 37.17M 34.79M 31.53M 59.55M 4.04B 59.98M 418M 163M 2.06B 157M 154M 6.62B | 57M 50.6M 47.35M 42.92M 81.05M 5.49B 81.64M 569M 221M 2.8B 214M 209M 9.01B |
| Net income | -245M -217M -203M -184M -348M -23.59B -350M -2.44B -950M -12.03B -918M -899M -38.68B | -354M -314M -294M -266M -503M -34.1B -507M -3.53B -1.37B -17.4B -1.33B -1.3B -55.92B |
| Net Debt | -88.02M -78.13M -73.12M -66.27M -125M -8.48B -126M -878M -342M -4.33B -330M -323M -13.92B | -210M -187M -175M -158M -299M -20.28B -301M -2.1B -816M -10.35B -790M -773M -33.26B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
